Antibody blocking of cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1) reduces the inhibition of anti-tumor cytotoxic T-cell responses resulting from the release of negative regulators of immune activation called immune checkpoints (IC) [75]. Here, PDCD1 is linked to neoplasm.